The DOI matches its Crossref record.
Approval of Novel TB Drug Celebrated—With Restraint
Abstract
On New Year's Eve, the U.S. Food and Drug Administration approved the first new tuberculosis drug in more than 40 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bedaquiline was the first new drug approved in more than 40 years (ref. 121 )”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [121]
Citations
Cited by
Sorted by citations
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A. I., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 921
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 448
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 391
“From these new rug candidates, the semi-synthetic TMC207 has received FDA pproval, specifically for patients with MDR-TB, through its accelerted approval programme which based its decision on Phase II trials Cohen, 2013; Diacon et al., 2009, 2012).”
BackgroundInfluential
Metadata
- Authors
- Cohen, J.
- Venue
- Science
- Published
- 2013-01-11
- Volume
- 339
- Issue
- 6116
- Pages
- 130-130
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1972806716
- Cited by
- 166
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 17 · 2016: 18 · 2015: 18 · 2014: 18 · 2013: 24
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- tuberculosis, drug approval, FDA approval, tuberculosis treatment, drug development
- MeSH terms
- Antitubercular Agents, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Mycobacterium tuberculosis, Quinolines, United States, United States Food and Drug Administration, Drug Approval, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
